Mursla Bio was selected to present at the largest pharmaceutical and biotech partnering event
Cambridge, UK, 1st June 2023: Mursla Bio is delighted to announce its in-person presentation at the 2023 BIO International Convention taking place June 5–8, 2023 in Boston, MA, United States.
The event is the largest pharmaceutical and biotech partnering event globally and brings together a wide spectrum of life science and applications. It features notable guests such as the CEOs of GSK and Biogen as well as the current FDA commissioner. It is expected to attract 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships.
Pierre Arsène, Founder & CEO, will deliver the company’s presentation, discussing the latest developments of Mursla Bio. This event will take place on Wednesday 7th of June 2023 at 11:45 in Room 104A.
-ENDS-
MEDIA RELATIONS
For more information contact:
Limewash, Cambridge
Sarah Brereton, Director
Tel: +44 (0)7796 583 223
Email: sarah@limewash.co.uk
Mursla Bio, Cambridge
Pierre Arsène, Founder & CEO
Tel: +44 (0) 1223 928 141
Email: contact@mursla.com
About Mursla Bio
Mursla Bio (Cambridge, UK) is an emergent techbio company, leveraging extracellular vesicle biology to deliver nextgen liquid biopsy and precision medicine tests. Its first product is an In Vitro Diagnostics test to significantly improve the early detection of liver cancer among high-risk populations, such that more individuals can benefit from curative and lifesaving treatments. Mursla Bio’s test is first-in-class and is differentiated from first generation liquid biopsy tests using circulating free DNA as it is tissue-specific, multi-omics and offers a real time snapshot of disease biology. Mursla Bio was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category.
Discover more: mursla.com